Key facts
- It has raised $19.2M across 2 recorded rounds; the latest was Early Stage VC ($7.0M) in Apr 2024.
- Notable investors include MassChallenge, Harvard Innovation Launch Lab, Pillar VC, 380 Cap, Accanto Partners — 8 tracked in total.
- Adaptilens has filed 2 Form Ds with the SEC since 2023, most recently May 2024 ($7.0M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Adaptilens
Funding rounds
2 roundsAbout Adaptilens
Developer of an accommodating intraocular lens (IOL) designed to replicate the human lens. The company's lens mimics the natural human lens, giving patients clear near, intermediate, and distance vision, by allowing the eye's ciliary muscles to change the implanted lens's shape so that the eye can focus at a range of distances naturally, enabling patients to live their lives free of glasses and contact lenses.
- Sector
- Healthcare
- HQ
- Newton, MA, United States
- Founded
- 2019
- Employees
- 8
- Website
- adaptilens.com/
- Ownership
- Privately Held (backing)
Adaptilens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adaptilens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adaptilens in its N-PORT filings yet. We sweep new filings monthly.